相关实验视频
Updated: Jul 12, 2026
Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
对禽传染性支气管炎病毒的新型疫苗的开发和免疫保护评估
Benli Huang1, Sheng Chen1, Zhanxin Wang2
1State Key Laboratory of Swine and Poultry Breeding Industry & Heyuan Branch, Guangdong Provincial Laboratory of Lingnan Modern Agricultural Science and Technology, College of Animal Science, South China Agricultural University, Guangzhou, 510642, China; Guangdong Provincial Key Lab of AgroAnimal Genomics and Molecular Breeding, College of Animal Science, South China Agricultural University, Guangzhou, 510642, China; Guangdong Engineering Research Center for Vector Vaccine of Animal Virus, Guangzhou, 510642, China; Zhongshan Innovation Center of South China Agricultural University, Zhongshan 528400, China.
由于病毒的高突变率,开发针对传染性支气管炎 (IB) 的新型疫苗至关重要. H120-CSL复合疫苗候选人显示出对IBV最有效的免疫保护,为家禽生产提供了一个有前途的解决方案.
科学领域:
- 兽医病毒学 兽医病毒学
- 鸟类病理学 鸟类病理学
- 疫苗开发 疫苗开发
背景情况:
- 传染性支气管炎 (IB) 是一种影响家禽生产的传染性鸟类呼吸道疾病.
- 传染性支气管炎病毒 (IBV) 迅速发生突变,限制了疫苗的疗效,需要新的疫苗策略.
- 六种IBV菌株被评估了它们在新型疫苗开发中的潜力.
研究的目的:
- 为疫苗开发确定有前途的IBV菌株.
- 构建和评估表达S1和N蛋白质的复合疫苗候选人.
- 评估新型IBV候选疫苗的免疫性和保护性疗效.
主要方法:
- 对六种IBV菌株进行了致病性测试和血清交叉中和实验.
- 已经构建了复合疫苗候选者 (H120-FQH QX3和H120-CSL).
- 进行了免疫保护实验,以评估疫苗的疗效.
主要成果:
- FQH QX3菌株表现出最弱的致病性和最广泛的中和性,而CSL菌株是最致病性的.
- H120-CSL重组疫苗候选人证明了最有效的免疫保护.
- 在CSL菌株的S1和N基因表现出强大的免疫性.
结论:
- H120-CSL复合疫苗是针对传染性支气管炎进一步评估的有希望的候选人.
- CSL菌株的S1和N基因是未来IBV疫苗设计的合适抗原标.
- 新型疫苗策略对于应对禽类高度变异IBV菌株带来的挑战至关重要.
相关概念视频
01:51Vaccinations
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...